Determinants of cancer drug pricing and how to overcome the cancer premium von Vokinger, Kerstin N.

Volltext

Shortages of essential cancer medicines: who is responsible and what are the possible solutions? von Jenei, Kristina, Lythgoe, Mark P, Vokinger, Kerstin N

Volltext

Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015–20): a comparative analysis von Muehlematter, Urs J, Daniore, Paola, Vokinger, Kerstin N

Volltext

Lifecycle Regulation of Artificial Intelligence– and Machine Learning–Based Software Devices in Medicine von Hwang, Thomas J, Kesselheim, Aaron S, Vokinger, Kerstin N

Volltext

Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis von Vokinger, Kerstin N, Hwang, Thomas J, Grischott, Thomas, Reichert, Sophie, Tibau, Ariadna, Rosemann, Thomas, Kesselheim, Aaron S

Volltext

Mitigating bias in machine learning for medicine von Vokinger, Kerstin N., Feuerriegel, Stefan, Kesselheim, Aaron S.

Volltext

Adverse effects of acquisitions in the pharmaceutical industry von Newham, Melissa, Vokinger, Kerstin N.

Volltext

Digital health and the COVID-19 epidemic: an assessment framework for apps from an epidemiological and legal perspective von Vokinger, Kerstin Noelle, Nittas, Vasileios, Witt, Claudia M, Fabrikant, Sara Irina, von Wyl, Viktor

Volltext

Vertebral body insufficiency fractures: detection of vertebrae at risk on standard CT images using texture analysis and machine learning von Muehlematter, Urs J., Mannil, Manoj, Becker, Anton S., Vokinger, Kerstin N., Finkenstaedt, Tim, Osterhoff, Georg, Fischer, Michael A., Guggenberger, Roman

Volltext

Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany von Vokinger, Kerstin N, Nussli, Emanuel, Dusetzina, Stacie B

Volltext

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study von Hwang, Thomas J, Ross, Joseph S, Vokinger, Kerstin N, Kesselheim, Aaron S

Volltext

WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines von Jenei, Kristina, Glaus, Camille E G, Vokinger, Kerstin N

Volltext

Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: Prognostic scores as a way forward von Locher, Luca, Serra-Burriel, Miquel, Trapani, Dario, Nussli, Emanuel, Vokinger, Kerstin N.

Volltext

Sources of Innovation in Gene Therapies — Approaches to Achieving Affordable Prices von Vokinger, Kerstin N., Avorn, Jerry, Kesselheim, Aaron S.

Volltext

Strategies That Delay Market Entry of Generic Drugs von Vokinger, Kerstin Noëlle, Kesselheim, Aaron S, Avorn, Jerry, Sarpatwari, Ameet

Volltext

Reforming the World Health Organization’s Essential Medicines List: Essential but Unaffordable von Hwang, Thomas J, Kesselheim, Aaron S, Vokinger, Kerstin N

Volltext

AI Devices in Neurology—Moving From Diagnosis to Prognosis von Hillis, James M, Cliff, Edward R. Scheffer, Vokinger, Kerstin N

Volltext

Do Managed Entry Agreements Contribute to Lower Pharmaceutical Spending? von Vokinger, Kerstin N

Volltext

New EU regulation on health technology assessment of cancer medicines von Hwang, Thomas J, Vokinger, Kerstin N

Volltext

Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 von Vokinger, Kerstin N., Muehlematter, Urs Jakob

Volltext